Meta description: Hims & Hers Health (NYSE: HIMS) is back in the spotlight after a new $250 million buyback, expansion into Canada, and fresh acquisitions in lab testing and blood diagnostics. Here’s a comprehensive look at HIMS stock price, latest news, GLP‑1 risks, and Wall Street forecasts as of December 6, 2025.
Hims Stock Today: Price, Valuation and Volatility
As of the close on Friday, December 5, 2025, Hims & Hers Health (NYSE: HIMS) finished trading at around $39–39.3 per share, giving the telehealth company a market capitalization of roughly $8.9–9.0 billion. [1]
Over the last 12 months, HIMS has traded between about $24 at the low and $73 at the high, reflecting how sharply sentiment has swung since the company became one of the best‑known digital‑health growth stories. [2]
On fundamental metrics, Hims still screens as a high‑growth, high‑multiple stock:
- Trailing P/E: roughly 70–75x
- Price‑to‑sales: around 4x TTM revenue
- Beta: ~2.4, highlighting above‑market volatility [3]
In other words, the market is still paying a premium for Hims’ growth and recurring subscription model, even after a sizable pullback from its 2025 peaks.
The Big Picture: Why Hims Stock Matters Right Now
Going into 2026, three themes dominate the HIMS story:
- Hyper‑growth with real profits – revenue is up almost 50% year‑over‑year while the company remains profitable on a GAAP basis and generates strong free cash flow. [4]
- Aggressive expansion into weight loss, labs and diagnostics – including GLP‑1 weight‑loss drugs, a nationwide lab‑testing offering, and new acquisitions like YourBio Health and Canada’s Livewell. [5]
- A tug‑of‑war between bulls and bears over valuation and regulatory risk – visible in mixed Wall Street ratings, a wide range of price targets, and sharp price swings around GLP‑1 and policy headlines. [6]
The past few weeks have brought a wave of fresh news that could shape the Hims stock trajectory into 2026, so let’s unpack it step by step.
Latest Hims Stock News as of December 6, 2025
1. $250 Million Share Buyback Signals Confidence
On November 17, 2025, Hims & Hers’ board authorized a new $250 million share repurchase program lasting through November 11, 2028. [7]
Key details:
- The company fully exhausted its prior $100 million buyback (launched in July 2024), repurchasing about 1.33 million shares for $55.5 million between October 1 and November 7, 2025, along with earlier repurchases. [8]
- The new authorization allows Hims to repurchase stock in the open market, via privately negotiated deals, and under Rule 10b5‑1 plans, giving management flexibility to buy on dips. [9]
Commentary from outlets tracking the move notes that the buyback runs directly alongside margin pressure and regulatory uncertainty, so it’s clearly meant to reinforce the narrative that management still sees long‑term upside in the equity despite volatility. [10]
2. Canada Expansion: New Market, New GLP‑1 Tailwind
On December 4, 2025, Hims & Hers officially entered the Canadian market, following the strategic acquisition of Livewell, a local digital health platform focused largely on weight‑loss care. [11]
Highlights from the Canada push:
- Hims is now serving Canadian customers for the first time, offering weight‑management programs and telehealth services tailored to local regulations. [12]
- The move is positioned as a way to ride expected demand for semaglutide‑based weight‑loss drugs (think Ozempic/Wegovy generics) once broader availability and regulation in Canada align. [13]
- Analysts have framed Canada as a new growth catalyst, with Seeking Alpha and other outlets arguing that international expansion should help diversify Hims’ revenue away from purely U.S. dynamics. [14]
Initial reaction: coverage from financial media notes that HIMS stock rose on the Canada news, even within a choppy tape, reinforcing the idea that investors still reward credible expansion moves. [15]
3. YourBio Health Acquisition: Owning the Blood Draw
On December 3, 2025, Hims announced a deal to acquire YourBio Health, a Boston‑based company best known for its TAP® microneedle blood‑sampling device, which enables virtually painless at‑home blood collection. [16]
Why it matters:
- YourBio’s tech slots neatly into Hims’ new Labs and diagnostic testing strategy, enabling the company to bring more of the testing experience into the home rather than relying solely on third‑party clinics. [17]
- Articles covering the deal emphasize that adding microneedle sampling could improve patient adherence, reduce friction, and significantly broaden the types of tests Hims can offer via subscription bundles. [18]
- The transaction is expected to close in 2026, subject to customary approvals, and is structured as an all‑cash acquisition (terms undisclosed). [19]
Short‑term, this isn’t a massive financial event by itself. Strategically, though, it pushes Hims further from being “just a telehealth prescription site” and closer to a vertically integrated preventive‑health platform.
4. Lab Testing: A New Billion‑Dollar Bet
In mid‑November, Hims rolled out its Labs offering nationwide, providing comprehensive bloodwork and biomarker testing via a partnership with Quest Diagnostics. [20]
Key features:
- A $199 annual plan for around 50 biomarkers, and a $499 plan with two blood draws and 120 biomarkers, covering heart health, hormones, stress markers, and more. [21]
- Customers go to one of 1,000+ Quest locations for the draw, view results online, and then receive care plans and prescriptions from Hims providers. [22]
- CEO Andrew Dudum has publicly said lab testing could eventually represent a $1 billion business, as Hims expands from reactive treatments (e.g., hair loss, ED) toward preventive and longitudinal care. [23]
Pair this with the YourBio deal, and the message is clear: Hims wants to own the dataplane of consumer health, not just sell pills.
Q3 2025 Earnings: Rapid Growth Meets Margin Pressure
Hims’ latest reported quarter (Q3 2025, released November 3) laid out the core fundamentals driving the stock debate. [24]
Headline numbers
For the quarter ended September 30, 2025:
- Total revenue: $599.0 million, up 49% year‑over‑year
- Online revenue: $589.1 million, up 50% YoY
- Subscribers: 2.47 million, up 21% YoY
- Monthly online revenue per average subscriber: $80, up 19% YoY [25]
Profitability:
- Gross margin: 74%, down from 79% a year ago
- Net income: $15.8 million vs. $75.6 million a year ago (prior quarter benefited from a large one‑time tax valuation allowance release)
- Adjusted EBITDA: $78.4 million vs. $51.1 million (+53% YoY)
- Free cash flow: $79.4 million, flat year‑on‑year but on a much larger revenue base [26]
Wall Street’s reaction was mixed:
- Hims beat revenue estimates (~$600m vs. ~$580m expected), highlighting strong demand. [27]
- EPS came in at $0.06 vs. $0.10 expected, a 40% downside surprise driven by higher investment and compressed gross margins. [28]
- After the report and guidance, several analyses noted that the stock fell 7–8% in the following days, with some pieces pointing to concerns over margins, GLP‑1 dependence, and stepped‑up spending. [29]
Updated guidance and long‑term goals
Management narrowed its 2025 guidance: [30]
- Q4 2025 revenue: $605–625m
- Full‑year 2025 revenue: $2.335–2.355bn (up ~59% YoY)
- Full‑year 2025 adjusted EBITDA: $307–317m (around 13% margin)
Longer term, Hims reiterated a $6.5 billion revenue target by 2030, and expects its GLP‑1 weight‑loss segment alone to generate about $725m in revenue by 2026, underscoring how central weight loss is becoming to the thesis. [31]
GLP‑1 Weight Loss: Hims’ Biggest Opportunity and Its Largest Risk
The Wegovy breakup (and possible reconciliation)
In June 2025, Novo Nordisk abruptly ended its partnership with Hims to sell branded Wegovy weight‑loss injections through the platform. HIMS stock fell more than 30% in a single session on the news. [32]
- Novo accused Hims of continuing to sell compounded semaglutide in ways it viewed as unlawful after the FDA declared the shortage over.
- Hims responded that it would continue offering “personalized” compounding for patients whose doses weren’t available from Novo and accused the drugmaker of trying to steer patients back to the branded drug. [33]
This clash highlighted two key risks:
- Regulatory scrutiny of compounded GLP‑1s and telehealth prescribing practices.
- Reputation and partnership risk with large pharma companies whose products are central to the obesity‑care boom.
Fast‑forward to Q3: Hims has disclosed that it is again in active negotiations with Novo Nordisk to offer both Wegovy injections and a future oral version through its platform, while still emphasizing its own compounded and alternative offerings. [34]
No definitive deal has been signed yet, and management has explicitly warned that there is no guarantee a new agreement will be reached. [35]
Policy shock: Trump’s promise to lower GLP‑1 prices
In October 2025, HIMS shares slid after a high‑profile campaign speech by former President Donald Trump promising to push down the prices of weight‑loss drugs such as Wegovy and Ozempic if elected. [36]
Coverage of that move underscored another layer of risk:
- If U.S. policy or drug‑pricing negotiations compress GLP‑1 margins, both drugmakers and telehealth intermediaries like Hims could see profitability squeezed.
- At the same time, lower prices might expand volume, which could benefit platforms with strong brand and user acquisition engines. [37]
For now, Hims continues to lean into GLP‑1s while building non‑GLP‑1 offerings in mental health, hair loss, sexual health, menopause, and preventive diagnostics to avoid being a one‑product story. [38]
Institutional Flows and Ownership: Who’s Buying HIMS?
New filings around December 6 provide a fresh look at how big money is positioning around Hims stock.
- Clear Street LLC recently disclosed a new position of 1,676,667 HIMS shares, valued at about $83.6 million. The stake represents roughly 0.75% of the company and is Clear Street’s 10th‑largest holding. [39]
- On the other hand, the State Board of Administration of Florida Retirement System cut its HIMS stake by 61.9% in Q2, trimming holdings to 43,040 shares worth about $2.1 million. [40]
- MarketBeat’s aggregation shows a steady churn of institutional holders adding and trimming positions, with institutional ownership around 63–64% of the float. [41]
This mix of new large entrants and selective de‑risking fits the broader narrative: Hims is widely owned but polarizing, with some funds treating dips as buying opportunities and others reducing exposure after the stock’s multi‑year run‑up.
Hims Stock Forecasts and Price Targets (2026–2030)
Wall Street analyst consensus
According to StockAnalysis, the 9 analysts currently covering HIMS have a consensus rating of “Hold” and an average 12‑month price target of $44.56, implying around 14% upside from the latest close in the high‑$39s. Price targets range from $30 on the low end to $85 at the high end, reflecting a very wide spread of views. [42]
Recent actions include: [43]
- BTIG (David Larsen) – Strong Buy, $85 target
- Canaccord Genuity (Maria Ripps) – Strong Buy, $68 target
- Bank of America (Allen Lutz) – Sell/Underperform, target raised from $28 to $32
- Truist Securities (Jailendra Singh) – Hold, trimmed target from $48 to $37
A separate aggregation by TickerNerd, looking at 21 analysts, finds:
- Median price target: $40
- Range: $25 to $85
- Rating mix: 2 Buy, 8 Hold, 3 Sell
- Implied upside: roughly 2% from a ~$39.20 share price at the time of analysis. [44]
Net‑net, traditional Wall Street coverage paints HIMS as neither a consensus bargain nor an obvious bubble—more a volatile growth stock where conviction depends heavily on one’s view of GLP‑1s, labs, and regulatory risk.
Fundamental valuation: Cash flows vs. multiples
A recent Simply Wall St deep dive highlights the valuation debate: [45]
- Using a discounted cash flow (DCF) model, they estimate fair value at about $58/share, suggesting HIMS might be roughly 31% undervalued vs. current prices around $39.
- However, on a P/E basis, Hims trades at about 68x earnings, compared with a healthcare‑sector average near 22x and peer averages ~30x—leading their “Fair P/E” framework to label the stock overvalued on multiples.
This illustrates why opinions diverge: if you believe the company can deliver the growth embedded in those models, the stock may still have room to run; if you’re skeptical, current multiples look demanding.
Quant and technical forecasts
Algorithmic and technical‑analysis‑driven forecasts are even more optimistic, but should be handled with caution:
- CoinCodex projects the share price to rise about 13% to ~$44.30 by early January 2026, and about 7–8% over the next year, with a long‑term model suggesting the stock could reach around $107 by 2030—more than doubling from current levels. [46]
- The same model labels HIMS a “good stock to buy” in its framework, but flags very high volatility (≈10–11% over 30 days) and a Fear & Greed Index reading of “Fear”, underscoring the risk of sharp drawdowns. [47]
These tools are not investment advice and rely heavily on historical price patterns and simplifying assumptions; they can be useful for understanding how traders are framing the stock, but they are not guarantees.
Bull vs. Bear Case for HIMS Heading Into 2026
The bull case
Supporters of Hims stock generally focus on several pillars:
- High growth with scale economics
- Huge addressable market in consumerized healthcare
- Expansion into GLP‑1 weight loss, lab testing, menopause, mental health and international markets opens multiple revenue streams beyond the original hair‑loss and ED niches. [50]
- Growing ecosystem moats
- Balance sheet and capital allocation
- Strong cash generation and a multi‑year $250m buyback that could offset dilution and support per‑share metrics. [53]
- DCF‑based upside
- Fundamental models projecting substantial growth in free cash flow over the next decade suggest potential undervaluation if management executes. [54]
The bear case
Skeptics raise a different set of concerns:
- Rich valuation vs. traditional metrics
- P/E and PEG ratios far above sector averages, leaving little room for execution missteps. [55]
- GLP‑1 and regulatory overhang
- The highly public dispute with Novo Nordisk, FDA scrutiny of compounded semaglutide, and political promises to lower GLP‑1 pricing all create headline and margin risk. [56]
- Margin compression
- Gross margin fell 500 basis points to 74% year‑on‑year in Q3, partly due to weight‑loss shipping and production costs; EPS also dropped sharply vs. the prior year. [57]
- Guidance and volatility
- Q4 guidance came in below some analyst expectations, and the stock has seen double‑digit percentage swings after earnings and policy headlines, which can be nerve‑racking for risk‑averse investors. [58]
- Competition
- Hims is fighting in a crowded space with rivals such as GoodRx, Ro, and LifeMD, many of which also have GLP‑1 programs and telehealth platforms. [59]
The result: a stock that can rip higher on positive news and sell off hard on negative surprises, even when fundamentals are trending upward.
What Today’s Data Means if You’re Watching HIMS
From a news and data standpoint as of December 6, 2025, Hims & Hers Health sits at an interesting crossroads:
- The core business is scaling fast and profitably, backed by a strong balance sheet and growing subscriber base. [60]
- Management is doubling down on long‑term bets in lab testing, diagnostics, and international expansion (Canada today, potentially more markets tomorrow). [61]
- At the same time, the valuation, GLP‑1 dependence, and regulatory uncertainty mean that expectations are high and the margin for error is thin. [62]
If you follow HIMS stock, some practical checkpoints to monitor into 2026 include:
- Any definitive deal (or breakdown) with Novo Nordisk on Wegovy distribution.
- Adoption and monetization of Labs and YourBio‑powered at‑home testing—do these become meaningful revenue contributors or just marketing sizzle?
- Margin trends, especially in GLP‑1 offerings, as scale and supply‑chain investments start to either pay off or weigh further on gross margin.
- Execution in Canada and other new geographies, showing whether Hims can replicate its U.S. playbook abroad.
- Updates to analyst forecasts and price targets as new data on revenue, earnings, and policy come in.
Important note
Nothing in this article is financial advice or a recommendation to buy or sell any security. It is a journalistic synthesis of publicly available information as of December 6, 2025. Always do your own research and consider speaking with a qualified financial professional before making investment decisions.
References
1. www.marketbeat.com, 2. www.marketbeat.com, 3. www.marketbeat.com, 4. investors.hims.com, 5. www.reuters.com, 6. stockanalysis.com, 7. investors.hims.com, 8. www.investing.com, 9. investors.hims.com, 10. longbridge.com, 11. markets.traderfox.com, 12. markets.traderfox.com, 13. markets.traderfox.com, 14. www.marketbeat.com, 15. markets.traderfox.com, 16. finance.yahoo.com, 17. finance.yahoo.com, 18. sherwood.news, 19. finance.yahoo.com, 20. www.wsj.com, 21. www.wsj.com, 22. www.wsj.com, 23. www.wsj.com, 24. investors.hims.com, 25. investors.hims.com, 26. investors.hims.com, 27. www.reuters.com, 28. www.investing.com, 29. swingtradebot.com, 30. investors.hims.com, 31. www.reuters.com, 32. www.reuters.com, 33. www.reuters.com, 34. investors.hims.com, 35. investors.hims.com, 36. www.investing.com, 37. www.investing.com, 38. www.reuters.com, 39. www.marketbeat.com, 40. www.marketbeat.com, 41. www.marketbeat.com, 42. stockanalysis.com, 43. stockanalysis.com, 44. tickernerd.com, 45. simplywall.st, 46. coincodex.com, 47. coincodex.com, 48. investors.hims.com, 49. investors.hims.com, 50. www.reuters.com, 51. www.wsj.com, 52. investors.hims.com, 53. investors.hims.com, 54. simplywall.st, 55. www.investing.com, 56. www.reuters.com, 57. investors.hims.com, 58. www.investors.com, 59. markets.traderfox.com, 60. investors.hims.com, 61. www.wsj.com, 62. simplywall.st
